Themis Medicare Limited Stock

Equities

THEMISMED

INE083B01024

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:49 2024-05-09 am EDT 5-day change 1st Jan Change
208 INR -3.08% Intraday chart for Themis Medicare Limited -5.63% -2.30%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2022 3.95B 47.3M Sales 2023 3.54B 42.47M Capitalization 10.73B 129M
Net income 2022 729M 8.74M Net income 2023 569M 6.82M EV / Sales 2022 2.33 x
Net Debt 2022 595M 7.13M Net Debt 2023 798M 9.57M EV / Sales 2023 3.25 x
P/E ratio 2022
11.8 x
P/E ratio 2023
18.9 x
Employees 996
Yield 2022
0.54%
Yield 2023
0.43%
Free-Float 21.11%
More Fundamentals * Assessed data
Dynamic Chart
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Themis Medicare Limited Launches REMITHEM CI
Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Themis Medicare Limited Announces Incorporation of Wholly Owned Subsidiary CI
Themis Medicare Limited Announces Cessation of Vijay Agarwal as Independent Director CI
Themis Medicare Limited Appoints Reena Patel as Alternate Non-Executive Non- Non-Independent Director to Dr. Adam Demeter, Effective September 11, 2023 CI
Themis Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Themis Medicare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Themis Medicare Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Themis Medicare Limited Recommends Dividend for Financial Year Ended 31 March 2023 CI
Themis Medicare Limited Announces Board Resignations CI
Themis Medicare Gets Drug Controller General of India’s No-Objection for Diclofenac Injection MT
Themis Medicare Announces DCGI Approval of Remifentanil Hydrochloride 1mg/2mg for Injection for Import and Marketing CI
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Themis Medicare Launches Drug for Treatment of Menopausal Symptoms in India MT
More news
1 day-3.08%
1 week-5.63%
Current month-5.63%
1 month-8.55%
3 months-5.35%
6 months+23.22%
Current year-2.30%
More quotes
1 week
207.05
Extreme 207.05
225.60
1 month
203.30
Extreme 203.3
230.00
Current year
192.75
Extreme 192.75
266.00
1 year
131.34
Extreme 131.34
266.00
3 years
43.48
Extreme 43.475
266.00
5 years
13.99
Extreme 13.99
266.00
10 years
6.22
Extreme 6.215
266.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 04-06-28
Director of Finance/CFO - 16-09-30
Chairman 75 72-12-31
Members of the board TitleAgeSince
Chief Executive Officer 49 04-06-28
Chairman 75 72-12-31
Director/Board Member 70 76-12-31
More insiders
Date Price Change Volume
24-05-09 208 -3.08% 6 677
24-05-08 214.6 -1.01% 4,136
24-05-07 216.8 +2.24% 4,518
24-05-06 212 -1.76% 4,244
24-05-03 215.8 -0.87% 6,053

Delayed Quote Bombay S.E., May 09, 2024 at 06:00 am EDT

More quotes
Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. The Company specializes in manufacturing a range of products for application areas like pain management, critical care and anti-infectives. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. THEMISMED Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW